within Pharmacolibrary.Drugs.ATC.A;

model A10BD12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.058333333333333334,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.038,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0016666666666666668,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Pioglitazone and sitagliptin is a fixed-dose combination of an oral antidiabetic thiazolidinedione (pioglitazone) and a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin) used in the management of type 2 diabetes mellitus. Pioglitazone increases insulin sensitivity, while sitagliptin enhances incretin hormone levels, leading to improved glycemic control. This combination is approved in several countries for use as part of a comprehensive diabetes treatment regimen.</p><h4>Pharmacokinetics</h4><p>Estimated composite pharmacokinetic parameters for healthy adult subjects, based on published data for individual drugs (pioglitazone and sitagliptin), as no specific published population pharmacokinetic models for the fixed-dose combination were located.</p><h4>References</h4><ol><li><p>Lyseng-Williamson, KA (2007). Sitagliptin. <i>Drugs</i> 67(4) 587–597. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200767040-00007&quot;>10.2165/00003495-200767040-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17352516/&quot;>https://pubmed.ncbi.nlm.nih.gov/17352516</a></p></li><li><p>Burness, CB, &amp; Scott, LJ (2015). Dulaglutide: A Review in Type 2 Diabetes. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 29(6) 407–418. DOI:<a href=&quot;https://doi.org/10.1007/s40259-015-0143-4&quot;>10.1007/s40259-015-0143-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26423061/&quot;>https://pubmed.ncbi.nlm.nih.gov/26423061</a></p></li><li><p>Kadokura, T, et al., &amp; Smulders, R (2014). Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin. <i>Clinical pharmacokinetics</i> 53(11) 975–988. DOI:<a href=&quot;https://doi.org/10.1007/s40262-014-0180-z&quot;>10.1007/s40262-014-0180-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25316572/&quot;>https://pubmed.ncbi.nlm.nih.gov/25316572</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A10BD12;
